Developer docs
API playgroundTry for free, no card

Search company profiles

Genexpath

Full company profile

uuid000afk2

Namestring
Genexpath
Websiteurl
genexpath.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Genexpath is a molecular diagnostics company specializing in the precise genetic characterization of complex cancers, particularly non-Hodgkin's lymphomas and sarcomas. The company develops and commercializes CE-IVD diagnostic kits and research-use products built on its proprietary RT-MLPSeq technology (Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification with High-Throughput Sequencing), which enables semi-quantitative analysis of multiple genetic markers, mutations, and chromosomal translocations in a single assay using exon-exon junction targeting and Unique Molecular Identifiers. Core products include the LymphoSign Kit (CE-IVD, classifying 80+ NHL subtypes via 130+ genetic markers), the SarcomaFusion Test (CE-IVD, analyzing 140+ fusion transcripts), and the LymphoTranscript Test for peripheral T-cell lymphomas. These are complemented by the RT-MIS bioinformatics platform, an AI-driven classification tool trained on 3,000+ tumor profiles referencing WHO 2017 standards.

Genexpath operates as a subsidiary of the CLINISCIENCES GROUP, which provides worldwide distribution infrastructure spanning 20+ European countries, South Korea, the USA, and Brazil. The company sells CE-IVD diagnostic kits in multiple reaction-size configurations, offers custom panel solutions (10-100 markers) for research and clinical studies, and supplies research products through the CLINISCIENCES catalog. Pricing is quote-based through local distributors, with kit sales representing a one-time-license revenue model and custom panel services offered as project-based engagements. Customers include hospital and clinical pathology laboratories (primary), pharmaceutical and biotech companies, and public research centers.

The company holds ISO 13485:2016 certification through its parent group and integrates its workflow with Illumina sequencing platforms (MiSeq, NextSeq 500/550). Founded in 2020 in Rouen, France, Genexpath has received two rounds of incubation support from Normandie Incubation. Its RT-MLPSeq-based workflow requires minimal RNA input (50-500 ng), is compatible with FFPE samples, and delivers results within approximately 24 hours, positioning the company in the niche but clinically meaningful segment of high-specificity cancer subtyping diagnostics.

Short descriptiontext

Genexpath is a French molecular diagnostics subsidiary of CLINISCIENCES GROUP that develops CE-IVD kits and research panels built on proprietary RT-MLPSeq technology for the genetic characterization of non-Hodgkin's lymphomas, sarcomas, and T-cell lymphomas, selling to clinical laboratories, pharmaceutical companies, and research centers via a global distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRouen, France
HQ citystring
Rouen
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, cancer characterization, RT-MLPSeq technology, in vitro diagnostics, lymphoma classification
Industry4 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Kits
TypeOne Time License
Description

Sale of CE-IVD diagnostic kits including LymphoSign Kit (8, 16, 24, 48 reaction configurations) for non-Hodgkin's lymphoma classification, LymphoTranscript for peripheral T-cell lymphomas, and SarcomaFusion for sarcoma characterization.

genexpath.com
2Custom Panel Solutions
TypeOne Time License
Description

Custom panel development and production services for research projects, preclinical and clinical studies. Available for 32 or 64 samples, enabling gene expression and fusion transcript analysis for 10-100 markers of interest.

genexpath.com
3Research Products
TypeOne Time License
Description

Sale of research products including human biological samples (cardiac, skin, bone marrow tissues), antibodies, molecular biology kits, cell culture systems, nanomaterials, and lab reagents through the CLINISCIENCES catalog.

genexpath.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Supply Chain, Marketing or Sales, Personnel
Pricing details1 tier
1LymphoSign Test-Kit available in 4 reaction sizes
ModelUnit PricingBilling cadencePay-as-you-go
Notes

GEP-LS08 (8 reactions), GEP-LS16 (16 reactions), GEP-LS24 (24 reactions), GEP-LS48 (48 reactions). Prices quoted through local distributors. Contact distributor for pricing.

genexpath.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1LymphoSign
Description

CE-IVD diagnostic kit for classification of non-Hodgkin's lymphoma subtypes using RT-MLPSeq technology analyzing over 130 genetic markers

genexpath.com
+4 more records
Core offering1 text field

Genexpath develops and commercializes CE-IVD molecular diagnostic kits and custom panels based on its proprietary RT-MLPSeq technology for the characterization of cancers including non-Hodgkin's lymphomas, sarcomas, and peripheral T-cell lymphomas. Its flagship LymphoSign Kit simultaneously analyzes over 130 genetic markers to classify more than 80 NHL subtypes within 24 hours from tumor RNA, complemented by the RT-MIS AI-driven bioinformatics platform trained on 3,000+ tumor profiles.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Classification of 80+ Non-Hodgkin's lymphoma subtypes
+4 more records
Product overview1 text field

Genexpath is a molecular diagnostics company offering a portfolio of CE-IVD diagnostic tests and research-use products built on their proprietary RT-MLPSeq technology platform. The core offering includes the LymphoSign Kit (CE-IVD) for non-Hodgkin's lymphoma classification analyzing 130+ genetic markers, the SarcomaFusion Test (CE-IVD) for sarcoma diagnosis with 140+ fusion transcripts, and the LymphoTranscript Test for peripheral T-cell lymphoma characterization. These diagnostic products are complemented by the RT-MIS bioinformatics platform for data analysis and custom panel services for research applications. The company operates under the CLINISCIENCES GROUP and provides products to hospitals, research centers, and pharmaceutical companies.

Product and service5 records
1LymphoSign Kit
CategoryIn Vitro Diagnostic Kit
Description

CE-IVD diagnostic kit for classification of over 80 Non-Hodgkin's lymphoma subtypes through RT-MLPSeq analysis of 130+ genetic markers, with AI-driven classification via RT-MIS software. Available in 8, 16, 24, and 48 reaction configurations.

2SarcomaFusion Test
CategoryIn Vitro Diagnostic Kit
Description

CE-IVD diagnostic test for characterization of sarcomas by analyzing over 140 fusion transcripts using RT-MLPSeq technology.

3LymphoTranscript Test
CategoryIn Vitro Diagnostic Kit
Description

Diagnostic test for characterization of peripheral T-cell lymphomas through fusion transcript analysis using RT-MLPSeq technology.

4RT-MIS Platform
CategoryBioinformatics Software
Description

Bioinformatics platform for rapid analysis of NGS sequencing data, providing gene expression signatures and AI-predicted classifications for cancer diagnostics based on a database of more than 3,000 tumor profiles.

5Custom RT-MLPSeq Panels
CategoryCustom Diagnostic Services
Description

Custom RT-MLPSeq panel solution allowing selection of 10-100 markers of interest for research projects, preclinical and clinical studies, available for 32 or 64 samples, with turnkey in vitro testing and bioinformatics analysis.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or Integration
Description

Illumina sequencing platforms (MiSeq, NextSeq 500, NextSeq 550) are used for RT-MLPSeq library sequencing. The LymphoSign kit workflow is designed for compatibility with Illumina sequencers, enabling integration of Genexpath diagnostic solutions into existing laboratory infrastructure.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

CliniSciences Group is the parent company and primary distributor for Genexpath products. They maintain worldwide distribution capabilities covering Europe, Americas, and Asia with customer service and technical support infrastructure.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

NeoGenomics is a US-based clinical reference lab running lymphoma NGS panels (e.g., Lymphoma Profile) at scale, competing for the same clinical pathology customers Genexpath sells kits into, especially in North America.

TypeEmerging player
Description

Personalis offers the ImmunoID Next platform for tumor immunogenomics and is expanding into hematologic cancer applications, positioning it as a competing NGS-based oncology diagnostics vendor with deeper US presence.

TypeDirect peer
Description

HTG offers targeted gene-expression and fusion-detection assays for oncology using a proprietary extraction-free chemistry run on NGS, closely mirroring Genexpath's RT-MLPSeq FFPE workflow and lymphoma/sarcoma indication focus.

4ArcherDX (Invitae)
TypeDirect peer
Description

ArcherDX's Anchored Multiplex PCR (AMP) chemistry delivers targeted NGS fusion and expression profiling for solid tumors and hematologic malignancies, a direct technical analogue to Genexpath's RT-MLPSeq.

TypeDirect peer
Description

SOPHiA provides AI-driven analysis of NGS oncology panels including lymphoma applications, with a community-based data-sharing model analogous to Genexpath's RT-MIS tumor-profile database.

TypeDirect peer
Description

Asuragen developed the QuantideX qPCR fusion assays and Signatera-style oncology kits targeting hematologic malignancies and sarcomas, a similar niche-IVD oncology diagnostic franchise to Genexpath.

TypeBroad incumbent
Description

Illumina supplies the sequencers Genexpath's workflow depends on, plus its own AmpliSeq targeted oncology panels — making Illumina both a critical partner and a potential competitive incumbent.

TypeBroad incumbent
Description

Qiagen sells a broad portfolio of oncology NGS panels and bioinformatics (QIAseq, IPA) and competes with Genexpath across research and clinical diagnostics with much greater scale.

TypeBroad incumbent
Description

Thermo Fisher's Oncomine NGS panels and Ion Torrent platform offer targeted lymphoma and solid tumor profiling, providing a competing turnkey workflow for clinical pathology labs evaluating Genexpath's offering.

TypeBroad incumbent
Description

NanoString's nCounter and GeoMx platforms deliver multiplex gene-expression profiling in oncology, a comparable multi-marker approach to Genexpath's RT-MLPSeq with broader market adoption.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genexpath

Molecular Diagnosticsgenexpath.com

Genexpath is a French molecular diagnostics subsidiary of CLINISCIENCES GROUP that develops CE-IVD kits and research panels built on proprietary RT-MLPSeq technology for the genetic characterization of non-Hodgkin's lymphomas, sarcomas, and T-cell lymphomas, selling to clinical laboratories, pharmaceutical companies, and research centers via a global distributor network.

What Genexpath does

Genexpath is a molecular diagnostics company specializing in the precise genetic characterization of complex cancers, particularly non-Hodgkin's lymphomas and sarcomas. The company develops and commercializes CE-IVD diagnostic kits and research-use products built on its proprietary RT-MLPSeq technology (Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification with High-Throughput Sequencing), which enables semi-quantitative analysis of multiple genetic markers, mutations, and chromosomal translocations in a single assay using exon-exon junction targeting and Unique Molecular Identifiers. Core products include the LymphoSign Kit (CE-IVD, classifying 80+ NHL subtypes via 130+ genetic markers), the SarcomaFusion Test (CE-IVD, analyzing 140+ fusion transcripts), and the LymphoTranscript Test for peripheral T-cell lymphomas. These are complemented by the RT-MIS bioinformatics platform, an AI-driven classification tool trained on 3,000+ tumor profiles referencing WHO 2017 standards.

Genexpath operates as a subsidiary of the CLINISCIENCES GROUP, which provides worldwide distribution infrastructure spanning 20+ European countries, South Korea, the USA, and Brazil. The company sells CE-IVD diagnostic kits in multiple reaction-size configurations, offers custom panel solutions (10-100 markers) for research and clinical studies, and supplies research products through the CLINISCIENCES catalog. Pricing is quote-based through local distributors, with kit sales representing a one-time-license revenue model and custom panel services offered as project-based engagements. Customers include hospital and clinical pathology laboratories (primary), pharmaceutical and biotech companies, and public research centers.

The company holds ISO 13485:2016 certification through its parent group and integrates its workflow with Illumina sequencing platforms (MiSeq, NextSeq 500/550). Founded in 2020 in Rouen, France, Genexpath has received two rounds of incubation support from Normandie Incubation. Its RT-MLPSeq-based workflow requires minimal RNA input (50-500 ng), is compatible with FFPE samples, and delivers results within approximately 24 hours, positioning the company in the niche but clinically meaningful segment of high-specificity cancer subtyping diagnostics.

Genexpath firmographics

Firmographics
Name
Genexpath
Website
https://genexpath.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Genexpath is a French molecular diagnostics subsidiary of CLINISCIENCES GROUP that develops CE-IVD kits and research panels built on proprietary RT-MLPSeq technology for the genetic characterization of non-Hodgkin's lymphomas, sarcomas, and T-cell lymphomas, selling to clinical laboratories, pharmaceutical companies, and research centers via a global distributor network.
Ownership category
akta.pro rank

Genexpath industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Molecular diagnostics
  • Cancer characterization
  • RT-MLPSeq technology
  • In vitro diagnostics
  • Lymphoma classification

Where Genexpath is headquartered

Location

Headquarters

HQ city
Rouen
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Genexpath business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Operations, Supply Chain, Marketing or Sales, Personnel

Revenue model

  1. Diagnostic Kits: Sale of CE-IVD diagnostic kits including LymphoSign Kit (8, 16, 24, 48 reaction configurations) for non-Hodgkin's lymphoma classification, LymphoTranscript for peripheral T-cell lymphomas, and SarcomaFusion for sarcoma characterization.
  2. Custom Panel Solutions: Custom panel development and production services for research projects, preclinical and clinical studies. Available for 32 or 64 samples, enabling gene expression and fusion transcript analysis for 10-100 markers of interest.
  3. Research Products: Sale of research products including human biological samples (cardiac, skin, bone marrow tissues), antibodies, molecular biology kits, cell culture systems, nanomaterials, and lab reagents through the CLINISCIENCES catalog.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goLymphoSign Test-Kit available in 4 reaction sizes

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Genexpath product offering

Product offering

Core offering

Genexpath develops and commercializes CE-IVD molecular diagnostic kits and custom panels based on its proprietary RT-MLPSeq technology for the characterization of cancers including non-Hodgkin's lymphomas, sarcomas, and peripheral T-cell lymphomas. Its flagship LymphoSign Kit simultaneously analyzes over 130 genetic markers to classify more than 80 NHL subtypes within 24 hours from tumor RNA, complemented by the RT-MIS AI-driven bioinformatics platform trained on 3,000+ tumor profiles.

Product overview

Genexpath is a molecular diagnostics company offering a portfolio of CE-IVD diagnostic tests and research-use products built on their proprietary RT-MLPSeq technology platform. The core offering includes the LymphoSign Kit (CE-IVD) for non-Hodgkin's lymphoma classification analyzing 130+ genetic markers, the SarcomaFusion Test (CE-IVD) for sarcoma diagnosis with 140+ fusion transcripts, and the LymphoTranscript Test for peripheral T-cell lymphoma characterization. These diagnostic products are complemented by the RT-MIS bioinformatics platform for data analysis and custom panel services for research applications. The company operates under the CLINISCIENCES GROUP and provides products to hospitals, research centers, and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

  • LymphoSign: CE-IVD diagnostic kit for classification of non-Hodgkin's lymphoma subtypes using RT-MLPSeq technology analyzing over 130 genetic markers
  • SarcomaFusion
  • LymphoTranscript
  • RT-MIS
  • RT-MLPSeq

Products and services

  • LymphoSign Kit CE-IVD diagnostic kit for classification of over 80 Non-Hodgkin's lymphoma subtypes through RT-MLPSeq analysis of 130+ genetic markers, with AI-driven classification via RT-MIS software. Available in 8, 16, 24, and 48 reaction configurations.
  • SarcomaFusion Test CE-IVD diagnostic test for characterization of sarcomas by analyzing over 140 fusion transcripts using RT-MLPSeq technology.
  • LymphoTranscript Test Diagnostic test for characterization of peripheral T-cell lymphomas through fusion transcript analysis using RT-MLPSeq technology.
  • RT-MIS Platform Bioinformatics platform for rapid analysis of NGS sequencing data, providing gene expression signatures and AI-predicted classifications for cancer diagnostics based on a database of more than 3,000 tumor profiles.
  • Custom RT-MLPSeq Panels Custom RT-MLPSeq panel solution allowing selection of 10-100 markers of interest for research projects, preclinical and clinical studies, available for 32 or 64 samples, with turnkey in vitro testing and bioinformatics analysis.

Quantifiable outcome

  • Classification of 80+ Non-Hodgkin's lymphoma subtypes
  • +4 more outcomes

Companies that use Genexpath

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Genexpath technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Genexpath partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • IlluminacoreTechnology or IntegrationIllumina sequencing platforms (MiSeq, NextSeq 500, NextSeq 550) are used for RT-MLPSeq library sequencing. The LymphoSign kit workflow is designed for compatibility with Illumina sequencers, enabling integration of Genexpath diagnostic solutions into existing laboratory infrastructure.
  • CliniSciences GroupcoreChannel Partner/ Reseller/ DistributorCliniSciences Group is the parent company and primary distributor for Genexpath products. They maintain worldwide distribution capabilities covering Europe, Americas, and Asia with customer service and technical support infrastructure.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Genexpath competitors and assessment

Company assessment

Regional players

  • NeoGenomics: NeoGenomics is a US-based clinical reference lab running lymphoma NGS panels (e.g., Lymphoma Profile) at scale, competing for the same clinical pathology customers Genexpath sells kits into, especially in North America.

Emerging players

  • Personalis: Personalis offers the ImmunoID Next platform for tumor immunogenomics and is expanding into hematologic cancer applications, positioning it as a competing NGS-based oncology diagnostics vendor with deeper US presence.

Direct peers

  • HTG Molecular Diagnostics: HTG offers targeted gene-expression and fusion-detection assays for oncology using a proprietary extraction-free chemistry run on NGS, closely mirroring Genexpath's RT-MLPSeq FFPE workflow and lymphoma/sarcoma indication focus.
  • ArcherDX (Invitae): ArcherDX's Anchored Multiplex PCR (AMP) chemistry delivers targeted NGS fusion and expression profiling for solid tumors and hematologic malignancies, a direct technical analogue to Genexpath's RT-MLPSeq.
  • SOPHiA GENETICS: SOPHiA provides AI-driven analysis of NGS oncology panels including lymphoma applications, with a community-based data-sharing model analogous to Genexpath's RT-MIS tumor-profile database.
  • Asuragen (now part of Bio-Techne): Asuragen developed the QuantideX qPCR fusion assays and Signatera-style oncology kits targeting hematologic malignancies and sarcomas, a similar niche-IVD oncology diagnostic franchise to Genexpath.

Broad incumbents

  • Illumina (AmpliSeq for Illumina): Illumina supplies the sequencers Genexpath's workflow depends on, plus its own AmpliSeq targeted oncology panels — making Illumina both a critical partner and a potential competitive incumbent.
  • Qiagen (QIAseq targeted panels): Qiagen sells a broad portfolio of oncology NGS panels and bioinformatics (QIAseq, IPA) and competes with Genexpath across research and clinical diagnostics with much greater scale.
  • Thermo Fisher Scientific (Oncomine panels): Thermo Fisher's Oncomine NGS panels and Ion Torrent platform offer targeted lymphoma and solid tumor profiling, providing a competing turnkey workflow for clinical pathology labs evaluating Genexpath's offering.
  • NanoString Technologies (now Bruker Spatial Biology): NanoString's nCounter and GeoMx platforms deliver multiplex gene-expression profiling in oncology, a comparable multi-marker approach to Genexpath's RT-MLPSeq with broader market adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Genexpath social profiles

Digital presence

Genexpath compliance and trust

Trust signal

Compliance1 record

Genexpath financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genexpath leadership team

Management profile

Number of profiles

Genexpath funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genexpath M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genexpath

What does Genexpath do?

Genexpath develops and commercializes CE-IVD molecular diagnostic kits and custom panels based on its proprietary RT-MLPSeq technology for the characterization of cancers including non-Hodgkin's lymphomas, sarcomas, and peripheral T-cell lymphomas. Its flagship LymphoSign Kit simultaneously analyzes over 130 genetic markers to classify more than 80 NHL subtypes within 24 hours from tumor RNA, complemented by the RT-MIS AI-driven bioinformatics platform trained on 3,000+ tumor profiles.

Is Genexpath a public or private company?

Genexpath is a private company. It is classified as corporate owned and is currently operating.

When was Genexpath founded?

Genexpath was founded in 2020. It employs 1 to 10 people.

Where is Genexpath based?

Genexpath is headquartered in Rouen, France, in the Europe region.

How does Genexpath make money?

Three revenue lines are on record. Diagnostic Kits are the primary driver. The others are custom Panel Solutions and research Products.

Who are Genexpath's main competitors?

NeoGenomics is listed as a regional player. Personalis is listed as an emerging player. Direct peers are HTG Molecular Diagnostics, ArcherDX (Invitae), SOPHiA GENETICS and Asuragen (now part of Bio-Techne). Broad incumbents are Illumina (AmpliSeq for Illumina), Qiagen (QIAseq targeted panels), Thermo Fisher Scientific (Oncomine panels) and NanoString Technologies (now Bruker Spatial Biology).

Does Genexpath have an API?

No public API is recorded for Genexpath.

What industry is Genexpath in?

Genexpath's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals